Technology | 2023.01.04
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties AMSTERDAM, SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]ate-adc-program-301713740.html
